Nemes Rush Group’s Novo Nordisk NVO Stock Holding History

Nemes Rush Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.1K	Hold	106	–	–	﹤0.01%	662
2026 Q1	$3.88K	Sell	106 -112	-51%	-$5.31K	﹤0.01%	665
2025 Q4	$11.1K	Buy	218 +55	+34%	+$2.81K	﹤0.01%	536
2025 Q3	$9.02K	Sell	163 -17,961	-99%	-$1.05M	﹤0.01%	500
2025 Q2	$1.25M	Sell	18,124 -78,992	-81%	-$5.37M	0.14%	90
2025 Q1	$6.74M	Buy	97,116 +13,951	+17%	+$1.15M	0.85%	39
2024 Q4	$7.15M	Sell	83,165 -10,198	-11%	-$1.1M	0.88%	37
2024 Q3	$12M	Sell	93,363 -6,915	-7%	-$922K	1.74%	19
2024 Q2	$14.3M	Buy	100,278 +6,114	+6%	+$810K	1.97%	15
2024 Q1	$12.1M	Buy	94,164 +93,708	+20,550%	+$11.2M	1.73%	19
2023 Q4	$47.2K	Buy	456 +27	+6%	+$2.67K	0.01%	260
2023 Q3	$39K	Sell	429 -93	-18%	-$8.19K	0.01%	279
2023 Q2	$42.2K	Buy	+522	New	+$42.6K	0.01%	286

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Nemes Rush Group's NVO Position: Q2 2026 in Review

Nemes Rush Group held its Novo Nordisk (NVO) position steady in Q2 2026 at 106 shares worth $5.1K. The position accounts for ﹤0.01% of the portfolio, ranked #662.

Nemes Rush Group first reported a position in NVO in Q2 2023 and has held it in 13 quarters since. The position peaked at $14.3M in Q2 2024. 1,354 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Nemes Rush Group held 106 shares of Novo Nordisk worth $5.1K as of Q2 2026.
Nemes Rush Group left its Novo Nordisk share count unchanged in Q2 2026.
Novo Nordisk made up ﹤0.01% of Nemes Rush Group's portfolio in Q2 2026, its #662 holding.
Nemes Rush Group first reported a position in Novo Nordisk in Q2 2023 and has held it in 13 quarters since.
Nemes Rush Group's Novo Nordisk position peaked at $14.3M in Q2 2024.
1,354 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.